Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Vertex Pharmaceuticals” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 159
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 159 pipeline programs matching "Vertex Pharmaceuticals" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

159 results for “Vertex Pharmaceuticals” Back to intelligence hub

Search results

Page 1 of 7
  1. Biological/Vaccine

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 3 mab active

    1 trial
  2. CTX001

    Vertex Pharmaceuticals (Australia) Pty.

    Beta-Thalassemia

    phase 3 mab active

    1 trial
  3. CTX001-111

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent β-thalassemia (TDT)

    phase 3 small molecule active

    1 trial
  4. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease, Transfusion dependent thalassemia

    phase 3 small molecule active

    1 trial
  5. ELX/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    19 trials
  6. Exa-cel

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease

    phase 3 mab terminated

    1 trial
  7. IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials
  8. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    16 trials
  9. LUM

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial
  10. Lumacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials
  11. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial
  12. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial
  13. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial
  14. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 small molecule completed

    2 trials
  15. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial
  16. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 mab completed

    1 trial
  17. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial
  18. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial
  19. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial
  20. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Genotype 1 Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial
  21. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial
  22. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 3 small molecule active

    3 trials
  23. Suzetrigine (SUZ)

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial
  24. TEZ

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.